Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 5/20 | 0.65 |
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | COPS5 | Q92905 | 4/20 | 0.48 |
| ▸ | STAMBP | O95630 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6084822 | 0.98 | PSMD14 (0.63) | PSMD14MGAMCOPS5STAMBPMEN1 | |
| SCHEMBL19346770 | 0.85 | PSMD14 (0.66) | PSMD14COPS5STAMBPHPGDSPARP1 | |
| SCHEMBL20821492 | 0.85 | PSMD14 (0.48) | PSMD14MGAMCOPS5STAMBPHPGDS | |
| SCHEMBL29688144 | 0.85 | PSMD14 (0.66) | PSMD14COPS5STAMBPHPGDSPARP1 | |
| SCHEMBL2204711 | 0.81 | PSMD14 (0.67) | PSMD14MGAMCOPS5STAMBPMEN1 | |
| SCHEMBL10464539 | 0.81 | PSMD14 (0.67) | PSMD14MGAMCOPS5STAMBPMEN1 | |
| SCHEMBL15861797 | 0.81 | PSMD14 (0.67) | PSMD14MGAMCOPS5STAMBPMEN1 | |
| SCHEMBL17502526 | 0.81 | PSMD14 (0.51) | PSMD14MGAMCOPS5STAMBPMEN1 | |
| SCHEMBL30859346 | 0.80 | CES2 (0.45) | PSMD14COPS5STAMBPHPGDSPARP1 | |
| SCHEMBL27398957 | 0.80 | CES2 (0.45) | PSMD14COPS5STAMBPHPGDSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117832755-A | Functional diaphragm for lithium-sulfur battery and preparation method thereof | 成都职业技术学院 | 2024-04-05 | — | — | CN | claimed |
| CN-1248968-A | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCRI receptor | PFIZER (US) | 2000-03-29 | — | — | CN | claimed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | claimed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250098677-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2025-03-27 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-12201113-B2 | Fungicidal compositions | SYNGENTA CROP PROTECTION AG (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20240315247-A1 | MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-12012399-B2 | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| CN-117832755-A | Functional diaphragm for lithium-sulfur battery and preparation method thereof | 成都职业技术学院 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024068656-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-04-04 | — | — | WO | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| CN-1248968-A | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCRI receptor | PFIZER (US) | 2000-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201113-B2 | Fungicidal compositions | CYP51A1, CYP4X1, CYP1B1 | PSMD14 3354/4885MGAM 29/4885COPS5 2189/4885 |
| US-12012399-B2 | Microbiocidal quinoline dihydro-(thiazine)oxazine derivatives | TLR1, TLR5, IDO1 | PSMD14 2489/4885MGAM 230/4885COPS5 2387/4885 |
| US-20250098677-A1 | FUNGICIDAL COMPOSITIONS | CYP51A1, CYP4X1, CYP1B1 | PSMD14 3354/4885MGAM 29/4885COPS5 2189/4885 |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | PSMD14 3557/4885MGAM 1794/4885COPS5 2188/4885 |
| US-20240315247-A1 | MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES | IFNG, TLR1, NOX1 | PSMD14 3685/4885MGAM 1272/4885COPS5 3709/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | PSMD14 3921/4885MGAM 3011/4885COPS5 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.